Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors  by Walker, Sarah et al.
Analytical Biochemistry 454 (2014) 17–22Contents lists available at ScienceDirect
Analytical Biochemistry
journal homepage: www.elsevier .com/locate /yabioDevelopment of an oligonucleotide-based ﬂuorescence assay
for the identiﬁcation of tyrosyl-DNA phosphodiesterase 1 (TDP1)
inhibitorshttp://dx.doi.org/10.1016/j.ab.2014.03.004
0003-2697/ 2014 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
⇑ Corresponding authors. Fax: +44 1273 876687.
E-mail addresses: s.el-khamisy@shefﬁeld.ac.uk (S. El-Khamisy), Simon.Ward@
sussex.ac.uk (S. Ward), J.Atack@sussex.ac.uk (J.R. Atack).
1 Abbreviations used: ATA, aurintricarboxylic acid; CPT, camptothecin; DSB, double-
strand breaks; SSB, single-strand breaks; TDP1, tyrosyl-DNA-phosphodiesterase 1;
TOP1, Topoisomerase 1; TOP1-CC, TOP1-DNA intermediates are termed cleavage
complexes; WCE, whole cell extracts.Sarah Walker a, Cornelia Meisenberg b, Rachel A. Bibby c, Trevor Askwith a, Gareth Williams a,
Frauke H. Rininsland d, Laurence H. Pearl c, Antony W. Oliver c, Sherif El-Khamisy b,e,⇑, Simon Ward a,⇑,
John R. Atack a,⇑
a Translational Drug Discovery Group, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, UK
bWellcome Trust DNA Repair Group, Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK
cCancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, University of Sussex, Science Park Road, Brighton BN1 9RQ, UK
dGyrasol Technologies, 2029 Becker Drive, Lawrence, KS 66047, USA
eMammalian Genome Stability Group, Kreb’s Institute, University of Shefﬁeld, Firth Court, Western Bank, Shefﬁeld S10 2TN, UK
a r t i c l e i n f oArticle history:
Received 24 September 2013
Received in revised form 3 February 2014
Accepted 6 March 2014
Available online 14 March 2014
Keywords:
TDP1
Assay
High-throughput screen
Fragment
Inhibitor
Topoisomerasea b s t r a c t
Topoisomerase 1 (TOP1) generates transient nicks in the DNA to relieve torsional stress encountered dur-
ing the cellular processes of transcription, replication, and recombination. At the site of the nick there is a
covalent linkage of TOP1 with DNA via a tyrosine residue. This reversible TOP1-cleavage complex inter-
mediate can become trapped on DNA by TOP1 poisons such as camptothecin, or by collision with repli-
cation or transcription machinery, thereby causing protein-linked DNA single- or double-strand breaks
and resulting in cell death. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a key enzyme involved in the
repair of TOP1-associated DNA breaks via hydrolysis of 30-phosphotyrosine bonds. Inhibition of TDP1
is therefore an attractive strategy for targeting cancer cells in conjunction with TOP1 poisons. Existing
methods for monitoring the phosphodiesterase activity of TDP1 are generally gel based or of high cost.
Here we report a novel, oligonucleotide-based ﬂuorescence assay that is robust, sensitive, and suitable
for high-throughput screening of both fragment and small compound libraries for the detection of
TDP1 inhibitors. We further validated the assay using whole cell extracts, extending its potential
application to determine of TDP1 activity in clinical samples from patients undergoing chemotherapy.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).DNA Topoisomerase 1 (TOP1)1 generates a transient nick in the
DNA in order to enable relaxation of torsional stress, exerted on
the DNA during transcription and replication [1]. During this process,
the hydroxyl group of TOP1 Tyr723 becomes covalently bound to the
30-phosphate group of a DNA nick [2]. This TOP1-DNA intermediate
is normally transient and religation occurs rapidly on resolution of
supercoiling. However, when TOP1 encounters endogenous DNA le-
sions such as abasic sites or base damage, or when cells are exposed
to drugs such as the TOP1 poison camptothecin (CPT), TOP1 can stall
on the DNA [2]. These stalled TOP1-DNA intermediates are termedcleavage complexes (TOP1-CC). TOP1-CC may block the replicative
or transcriptional polymerases, and result in the formation of sin-
gle-strand breaks (SSB) or double-strand breaks (DSB) with TOP1
linked covalently to the 30-ends [3]. Cell death can result if these le-
sions are not efﬁciently repaired.
Repair of TOP1-CC is initiated by the degradation of the cova-
lently linked TOP1 by ubiquitin-mediated proteolysis [4]. Tyro-
syl-DNA phosphodiesterase 1 (TDP1) subsequently catalyses the
hydrolysis of 30-phosphodiester bonds between a tyrosine residue
and the 30-DNA phosphate [5]. TDP1 belongs to the phospholipase
D superfamily of enzymes that contain two conserved HKD motifs
[6]. These motifs contain conserved residues that cluster together
within the active site. Mutation of either histidine 263 or 493
within the conserved HKD motif results in loss of activity, demon-
strating that these residues are critical for TDP1 activity [6].
It is worth highlighting that TDP1 is a broad-spectrum 30-DNA end-
processing enzyme. For example, it can process 30-phosphoglycolate
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drugs [7] and can cleave apurinic/apyrimidinic site (AP) sites in-
duced by alkylating agents used in cancer therapy such as temozol-
omide [8,9]. Point mutations in the TDP1 catalytic site (H493R)
cause SCAN1 neurological disorder (spinocerebellar ataxia with ax-
onal neuropathy) where patients present with cerebellar atrophy
and peripheral neuropathy [10]. Cell lines derived from SCAN1 pa-
tients accumulate Top1-SSBs due to defects in SSB repair and they
are hypersensitive to CPT [11,12]. TDP1 is subject to posttransla-
tional modiﬁcations that control its cellular activity such as phos-
phorylation [13,14] and SUMOylation [15]; however the
contribution of these modiﬁcations to TDP1 cellular function in
cancer remains elusive.
Overexpression of TDP1 increases resistance to CPT [16,17] and
increased expression of TDP1 protein resulting in increased en-
zyme activity has been observed in a set of non-small-cell lung
cancer samples [18]. Increased expression of TDP1 has also been
observed in a panel of colorectal tumor specimens [2]. TDP1
inhibitors could therefore have broad clinical utility both as a
single-agent treatment in tumors with genetic backgrounds that
are sensitive to TDP1 inhibition and as a combination therapy in
conjunction with established TOP1 poisons, radiotherapy, or
temozolomide.
Current assays for the assessment of the tyrosyl DNA phospho-
diesterase activity of TDP1 in vitro have utilised a chromogenic
substrate [19], a biotinylated system [20], or an Alphascreen for-
mat [21]. Elegant studies have recently reported the use of oligonu-
cleotide substrates to monitor the AP-site cleavage activity of TDP1
[22] and as real-time biosensors in cellular material [23]. Here we
focused on determining the tyrosyl DNA phosphodiesterase activ-
ity of TDP1, which is the preferred activity in vivo and in vitro, and
is likely to be exploited in conjunction with camptothecin-derived
protocols for cancer therapy. A radiolabeled gel assay has been
widely adopted in the past but can be costly and time-consuming,
and is therefore not applicable to high-throughput screening regi-
mens. Previously reported chromogenic and biotinylated assays
utilised physiologically less relevant substrates and high enzyme
concentrations. Here, we describe the development of a robust,
sensitive, more cost efﬁcient assay for high-throughput screening
of fragment and small compound libraries to identify novel TDP1
inhibitors.Materials and methods
Cloning and puriﬁcation of recombinant human TDP1
A codon-optimised synthetic gene, encoding the catalytic
domain of human TDP1, was purchased from GenScript USA Inc.
Details of the expression construct are consistent with that de-
scribed in Interthal et al. [6]. Recombinant protein was expressed
in, then puriﬁed from Escherichia coli strain Rosetta2 (DE3) (Merck,
Darmstadt, Germany) using standard chromatography techniques,
following the protocol described by Interthal et al. [6].
Preparation of oligonucleotide substrates
Oligonucleotides of 13mer with a 30-phosphotyrosyl bond
conjugated with an FITC molecule were purchased from Midland
Certiﬁed Reagent (Midland, TX, USA).
Development of the TDP1 ﬂuorescence assay
The assay was developed in 384-well black plates in a ﬁnal
reaction volume of 15 lL. The ﬁnal concentration of assay buffer
was 50 mM Tris 8.0, 5 mM MgCl2, 80 mM KCl, 0.05% Tween 20,and 1 mM DTT. Reactions were initiated by addition of substrate
and plates were incubated at 25 C. Final concentrations of
6.25 pM TDP1 and 10 nM substrate were used for routine screen-
ing. Addition of quench reagent (2 lL sensor + 30 lL enhancer buf-
fer) (Gyrasol Technologies, KS, USA) stopped the reaction and
ﬂuorescence was subsequently monitored with excitation and
emission wavelengths of kex 490 nm and kem 520 nm using a
BMG Labtech Pherastar plate reader. In vitro 30-tyrosyl-DNA
phosphodiesterase 1 activity of whole cell extracts (WCE) was
determined using the TDP1 ﬂuorescence assay format in a 15 lL
reaction volume. Final concentrations of WCE (ng/lg) per well, di-
luted in assay buffer, were incubated with 10 nM ﬁnal concentra-
tion of oligonucleotide substrate.Data analysis
Data were analysed using GraphPad Prism (GraphPad Software
Inc., La Jolla, CA). The afﬁnity of the substrate for the enzyme, the
Michaelis constant (or Km value), was determined according to the
Michaelis–Menten equation: Y = Vmax  X/(Km + X). The catalytic (or
ﬁrst-order rate) constant Kcat was calculated using the equation:
(Y = Et  kcat X/(Km + X)). IC50 values were generated by transform-
ing the data (X = Log(X)) and then ﬁtting these data to the equa-
tion: Y = Bottom + (Top–Bottom)/(1 + 10((LogEC50  X) ⁄ HillSlope)).
As an index of assay reproducibility, the statistical parameter Z-
prime (Z0) was calculated according to Zhang et al. [24].Fragment library single point screening
A library of 1500 fragments (Maybridge, Thermo Fisher Scien-
tiﬁc, UK) was screened, at a single point concentration of 1 mM
using the TDP1 ﬂuorescence assay as described.Cell culture
HEK293 cells were maintained at 5% CO2, in DMEM (Life Tech-
nologies, Paisley, UK) supplemented with 10% FCS, 100 U penicillin,
100 lg streptomycin, and 2 mM L-glutamine. TDP1/ mouse
embryonic ﬁbroblasts (MEF) [14,25,26] were maintained at 2% O2
in DMEM (Life Technologies, Paisley, UK) supplemented with 15%
FCS, 2 mM L-glutamine, 100 U penicillin, 100 lM nonessential ami-
no acids, and 100 lg streptomycin. TDP2/ DT40 cells containing
either a pcDNA3.1-HisC empty vector or pcDNA3.1-HisC encoding
human TDP2 were [27,28] maintained at 39 C, 5% CO2, in RPMI
(Life Technologies, Paisley, UK) supplemented with 10% FCS, 1%
chicken serum, 100 U penicillin, 100 lg streptomycin, 2 mM L-glu-
tamine, and 50 lM b-mercaptoethanol. For transient transfection
experiments, HEK293 cells were transfected with pCI empty vector
or pCI encoding human TDP1 [15] using Lipofectamine LTX with
Plus transfection reagent (Life Technologies, Paisley, UK), according
to the manufacturer’s instructions. Cell pellets were harvested 24 h
post transfection and stored at 80 C.Whole cell extract preparation
Cell pellets were resuspended in ice-cold lysis buffer (20 mM
Tris–HCl, pH 7.5, 10 mM EDTA, pH 8.0, 100 mM NaCl, 1% Triton
X-100) containing 1 ﬁnal concentration of complete mini EDTA-
free protease inhibitor cocktail (Roche Applied Science, Burgess
Hill, UK) at a 1:4 pellet volume to lysis buffer ratio. Pellets were ex-
tracted for 30 min at 4 C and the suspension was centrifuged at
13,000 rpm for 10 min at 4 C. Supernatant was collected and the
protein concentration determined by Bradford assay prior to ali-
quoting and storing at 80 C.
Fig. 2. Enzyme kinetics evaluation. (A) Enzyme titration and time course of TDP1 in
the Gyrasol assay. Final substrate concentration was 10 nM. (B) Kinetics of product
formation for two TDP1 concentrations. Final substrate concentration was 10 nM.
Graphs represent the mean of three independent experiments. Error bars represent
the standard deviation.
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Whole cell extract (40 lg) was separated by 10% SDS-polyacryl-
amide gel electrophoresis (PAGE) and transferred on to a Hybond-C
Extra nitrocellulose membrane (Fisher Scientiﬁc UK, Loughbor-
ough, UK). The membrane was blocked in 5% PBS-milk for 1 h prior
to immunoblotting. Antibodies against TDP1 (ab4166; Abcam,
Cambridge, UK) and TDP2 [22] were used overnight at a 1:2000
dilution in 5% PBST-milk. Actin antibodies (A4700; Sigma, Gilling-
ham, UK) were used at 1:3000 dilution in 5% PBST-milk for 1 h.
HRP-labeled polyclonal rabbit anti-mouse and polyclonal goat
anti-rabbit secondary antibodies were used at a 1:3000 dilution
in 5% PBST-milk and were obtained from Dako (Ely, UK). Blots were
developed using the chemiluminescent detection reagent, Super-
Signal West Pico chemiluminescent substrate (Fisher Scientiﬁc
UK, Loughborough, UK).
Results and discussion
Here we describe the combination of Gyrasol assay technology
(Fig. 1) with a ﬂuorescent oligonucleotide substrate in order to
identify novel TDP1 inhibitors. Gyrasol assay technology employs
the use of a small molecular, nonﬂuorescent trivalent metal ion
sensor to bind to the phosphate backbone of the DNA oligonucleo-
tide. The ﬂuorescence of any ﬂuorophore in close proximity to the
sensor is quenched by electron transfer. Any ﬂuorophore that is
separated from the DNA by a distance of greater than approxi-
mately 1 nm is too distant for electron transfer quench. The action
of TDP1 on the phosphotyrosine moiety on the oligonucleotide
substrate cleaves the FITC molecule. The increased distance of
cleaved FITC molecules from the DNA prevents quenching and
therefore speciﬁc tyrosyl DNA phosphodiesterase activity of TDP1
can be monitored as an increase in ﬂuorescence intensity.
The ability of WT TDP1 to cleave the phosphotyrosine bond
present on the ﬂuorescent-tagged oligonucleotide was determined
at different enzyme concentrations over a short time course
(Fig. 2A). Two concentrations from this initial time course were
then examined in detail in a 3-time course experiment (Fig. 2B).
These data demonstrated that the assay signal was dependent on
both time and enzyme concentration. Readings before addition of
quench reagent showed that ﬂuorescence readings in the absence
of quench reagent were uniform across the plate (4000 RFU for
10 nM substrate). On addition of quench reagent consistent back-
ground and activity ﬂuorescence readings were obtained for wellsFig. 1. Gyrasol assay technology. A 13mer oligo with a 30-tyrosine-conjugated FITC molec
be hydrolysed by tyrosyl-DNA-phosphodiesterase 1 (TDP1). Addition of a small molecula
to the phosphate bone of the ss-DNA oligo. The ﬂuorescence of any ﬂuor in close proximi
DNA (1 nm; 10 A) is too distant for electron transfer quench.with or without TDP1, indicating that the ﬂuorescence readings
obtained were speciﬁc for TDP1 activity (data not shown). The
enzyme concentration employed for further optimisation of the
assay was 6.25 pM, reﬂecting the efﬁcient turnover of the
oligonucleotide substrate by TDP1.
The Km for the oligonucleotide substrate was calculated
to be 49 ± 8 nM (Fig. 3A) under the assay conditions employed
and the Kcat was determined to be 107.1 ± 5.4 min1. These data
are in agreement with published studies of TDP1 activity onule was produced. The phosphodiester bond between the tyrosine and the DNA can
r, nonﬂuorescent trivalent metal ion sensor (MIII) (Gyrasol Technologies, USA) binds
ty to the sensor is quenched by electron transfer, while any ﬂuor separated from the
Fig. 3. Km determination and DMSO tolerance of TDP1. (A) 6.25 pM TDP1 was
incubated with increasing substrate concentrations for 10 min prior to addition of
quench reagent. Fluorescence signal was measured and the rate of product
formation calculated. Data were ﬁtted to the Michaelis–Menten equation using
GraphPad Prism. Graph represents the mean of three independent experiments.
Error bars represent the standard deviation. (B) A 6.25 pM TDP1 was incubated with
increasing concentrations of DMSO for 15 min prior to incubation with 10 nM
oligonucleotide substrate for 10 min. Quench reagent was then added and
ﬂuorescence signal measured. Graph represents the mean of three independent
experiments. Error bars represent the standard deviation.
Fig. 4. TDP1 mutant proteins. Recombinant mutant TDP1 proteins (6.25 pM) as
described in the text were incubated with a ﬁnal concentration of 10 nM
oligonucleotide substrate over a 3-h time course. Quench reagent was then added
and ﬂuorescence signal measured. Graph represents the mean of three independent
experiments. Error bars represent the standard deviation.
Fig. 5. Testing of reference inhibitors. Inhibition of TDP1 by suramin, sodium
orthovanadate, and ATA as determined in the Gyrasol assay.
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tion of 10 nM oligonucleotide substrate was selected for use in
fragment library screening. This concentration provided a good sig-
nal to noise ratio while using minimal substrate to enable the assay
to remain cost-effective to run.
Using the conditions described above, the assay was linear for
approximately 30 min. For screening purposes, the reaction was
incubated for 10 min prior to the addition of quench reagent and
immediate ﬂuorescence monitoring. Under these conditions a sig-
nal to noise ratio of 3:1 was achieved. While the addition of quench
appeared to stop the reaction, further incubation of the plate in the
presence of the quench reagent caused increased background read-
ings, potentially due to precipitation of quenching reagents.
In order to screen potential inhibitors of TDP1, the tolerance of
the enzyme to DMSO was determined. Under these assay condi-
tions, the enzyme was found to be tolerant to high levels of DMSO
(10%) with little or no loss of signal (Fig. 3B).
To further validate the assay a range of recombinant mutant
TDP1 proteins were tested at the same concentration under the
optimised assay conditions described. Recombinant proteins
tested included full-length TDP1, C terminal TDP1 containing the
catalytic domain only, and mutants of the S81 phosphorylation site
[14] and the K111 SUMOylation site [15]. All recombinant mutant
proteins were found to be active in the assay (data not shown),
with the exception of the H493N mutant protein. This mutation
recapitulates the H493R mutation identiﬁed in SCAN1 patientswhere the enzyme loses more than 95% of its catalytic activity
[30]. As expected, little to no turnover of the substrate was ob-
served on incubation of the substrate with TDP1 H493N (Fig. 4).
A number of reference TDP1 inhibitory compounds were tested
to verify that the assay is suitable for screening novel inhibitors.
Suramin, sodium orthovanadate, and aurintricarboxylic acid
(ATA) were all found to inhibit Tdp1 in this assay with IC50 values
of 5 lM, 4 lM, and 22 nM, respectively (Fig. 5). The IC50 data ob-
tained for suramin and ATA using this assay are in agreement with
published data [22].
Importantly, the enzyme and substrate concentrations de-
scribed above are signiﬁcantly lower than those of previously de-
scribed formats [20,21], demonstrating the improved sensitivity
of this assay. The low enzyme and substrate concentrations em-
ployed enable an extremely cost effective approach to the screen-
ing of large compound libraries.
A library of 1500 fragments was then screened at a single con-
centration of 1 mM. Fragments are expected to be weak enzyme
inhibitors and are therefore commonly screened at a higher con-
centration than standard compound libraries [31,32]. The plate Z
factor is a statistical measurement calculated from the means
and variance of both the negative and the positive controls on each
plate. A plate Z factor of above 0.5 indicates an excellent assay for
screening purposes [24]. Plate Z factors calculated from the nega-
tive (TDP1) and positive (+TDP1) control wells on each screening
plate were routinely observed to be >0.5 (data not shown),
although any plate with a Z factor of >0.4 was accepted. The
TDP1 ﬂuorescence assay was found to be extremely sensitive,
robust and highly suitable for screening of inhibitors for TDP1
30-phosphodiesterase activity.
-0.5 
0 
0.5 
1 
1.5 
2 
MEF TDP1 -/- MEF TDP1 +/+ R
el
a
ve
 F
lu
or
es
ce
nc
e 
un
it
s 
0.5 µg WCE 
1.0 µg WCE 
A  
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
 + Vector  + hTDP2 
DT40 TDP2 -/-  
Re
la

ve
 F
lu
or
es
ce
nc
e 
un
it
s 
0.25 µg WCE 
0.5 µg WCE 
B  
 + vector   + hTDP2 
DT40 TDP2 -/- 
hTDP2 
Acn 
C 
D E 
Acn 
hTDP1 
+ vector + hTDP1 
0 
0.5 
1 
1.5 
2 
+ vector  + hTDP1  
Re
la

ve
 F
lu
or
es
ce
nc
e 
 
un
it
s 
2.5 ng WCE 
5 ng WCE 
Fig. 6. TDP1 activity in whole cell extracts. Whole cell extracts (WCE) generated from HEK293 transfected with pCI empty vector or pCI vector for human TDP1
overexpression (A); wild-type or TDP1/ mouse embryonic ﬁbroblast (MEF)(C); and TDP2/ DT40 cells containing either pcDNA3.1-HisC empty vector or pcDNA3.1-HisC
vector for human TDP2 overexpression (D) were used as the TDP1 source in the TDP1 ﬂuorescent assay. The 15 lL reactions contained the indicated amounts of WCE. The
reaction was carried out at room temperature for 10 min and terminated by addition of quench reagent. Relative ﬂuorescence is shown and was calculated against the
ﬂuorescence obtained for 6.25 pM recombinant WT human TDP1 protein for each of three independent experiments. Error bars represent the standard deviation. WCEs
generated from HEK293 transfected with pCI empty vector or pCI vector for human TDP1 overexpression (B) and TDP2/ DT40 containing either pcDNA3.1-HisC empty
vector or pcDNA3.1-HisC vector for human TDP2 expression (E) were separated by 10% SDS-PAGE, followed by Western blotting analysis using antibodies against human
TDP2 and actin.
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could have important clinical applications in cancer patients.
Therefore we tested the ability of the TDP1 ﬂuorescence assay to
determine TDP1 activity levels in whole cell extracts from cells.
Whole cell extracts were generated from HEK293T cells trans-
fected with pCI vector for stable overexpression of human TDP1,
wild-type, and TDP1/ mouse embryonic ﬁbroblasts (MEF) and
from TDP2/ DT40 transfected with pcDNA3.1-HisC vector for hu-
man TDP2 overexpression [27]. WCE were then used as the TDP1
source in the TDP1 ﬂuorescence assay. Increased TDP1 activity
was observed in HEK293T WCE overexpressing TDP1 compared
to HEK293T WCE containing empty vector (Fig. 6A and B). In-
creased TDP1 activity was observed in the TDP1+/+ MEF WCE com-
pared to negligible activity in the TDP1/ MEF WCE (Fig. 6C).
Similar levels of activity were observed in TDP2+/+ and / DT40
cells, demonstrating that TDP2 is not able to contribute to cleavage
of the 30-phosphotyosine substrate under these conditions (Fig. 6D
and E). These results indicate that the activity observed is related
to the TDP1 cellular expression levels and that this assay may be
used to assess TDP1 activity from mouse, human, and chicken
material. The WCE assay could therefore be a useful tool forconﬁrming that inhibitors of TDP1 identiﬁed in biochemical
screens can also inhibit cellular TDP1. The speciﬁcity that we have
observed also indicates that the WCE assay could potentially be
used as a diagnostic tool for determination of TDP1 activity directly
in cancer cells or tissues from patients, thus identifying those pa-
tients that could beneﬁt from treatment with TDP1 inhibitors.
However, further work would need to be undertaken to conﬁrm
this application.
The identiﬁcation of TDP1 inhibitors could have important clin-
ical applications both in those patients where resistance to existing
treatments such as CPT is challenging and also potentially as
enhancers to radiotherapy treatments. Utilisation of biochemical
assays combined with a fragment-based drug design method to
synthesize newmolecules could be a powerful approach to the dis-
covery of novel oncology therapies.
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